Introduction
============

Mantle cell lymphoma (MCL) is a non-Hodgkin\'s lymphoma (NHL) composed of small lymphoid cells. Approximately 6% of lymphomas are classified as MCL. MCL generally occurs in adults with a median age of 60 years and has a male predominance ([@B1]). The primary presentation of extra-nodal disease occurs in one quarter of patients and frequently involves the Waldeyer\'s ring and gastrointestinal tract. Primary gastrointestinal MCL accounts for 1% to 4% of primary gastrointestinal lymphomas ([@B2]). Multiple lymphomatous polyposis (MLP) is one of the most common primary gastrointestinal presentations of MCL and accounts for 9% of primary gastrointestinal lymphomas ([@B3]). It frequently occurs in the colon and small bowel, particularly in the ileum and ileocecal region. However, MCL may also present endoscopically as the protruding type, fold-thickening type, ulceration type, and superficial type throughout the gastrointestinal tract ([@B4]).

Malignant lymphoma is an uncommon cause of intussusception, causing less than 1% of all cases of intussusception ([@B5]). A single protruding lesion in the small intestine combined with intussusception has never been reported in patients with MCL. We herein report a case of primary small intestinal MCL with a single protruding lesion causing ileocecal intussusception.

Case Report
===========

A 70-year-old previously healthy man presented with a 3-day history of constant pain in the right lower abdomen, associated with nausea, without a fever or weight loss. He had no history of gastrointestinal or hematological diseases or remarkable family history. A physical examination revealed normal vital signs, a soft distended abdomen with normoactive bowel sounds, and a palpable tender mass in the right lower quadrant. His laboratory data were as follows: white blood cell count, 6,400/μL; hemoglobin level, 13.0 g/dL; C-reactive protein level, 0.98 mg/dL; and soluble interleukin-2 receptor level, 790 U/m. Lactate dehydrogenase levels were normal. Contrast-enhanced computed tomography (CE-CT) of the abdomen showed intussusception and a mass in the terminal ileum ([Fig. 1](#g001){ref-type="fig"}). In addition, CE-CT of the neck, chest, and pelvis revealed no lymph node enlargement or organ involvement besides in the ileocecal region.

![Contrast-enhanced computed tomography scans of the abdomen. A, B: Target sign with a fat component in the right lower quadrant.](1349-7235-57-1751-g001){#g001}

Total colonoscopy demonstrated ileocolic intussusception and a large submucosal tumor-like protruding mass sinking into the cecum out of the terminal ileum. The mass had a smooth surface with multiple, irregularly shaped ulcerations and a diameter of about 50 mm ([Fig. 2A](#g002){ref-type="fig"}). The mass returned to the terminal ileum on colonoscopic manipulation, resolving the intussusception without operation ([Fig. 2B](#g002){ref-type="fig"}). Esophagogastroduodenoscopy revealed no involvement of the upper digestive tract.

![Endoscopic findings. A: Colonoscopy revealing ileocolic intussusception and a large submucosal tumor-like protruding mass entering the cecum and exiting the terminal ileum. B: The mass returned to the terminal ileum on colonoscopic manipulation.](1349-7235-57-1751-g002){#g002}

Multiple biopsies of the mass showed diffuse infiltration of monotonous small to small-to-medium sized lymphoid cells ([Fig. 3A and B](#g003){ref-type="fig"}). In addition, an immunohistochemical analysis of the biopsy tissues demonstrated positive staining for CD20 and CD5 ([Fig. 3C and D](#g003){ref-type="fig"}); therefore, MCL was suspected. Surgery was planned to prevent intussusception from recurring.

![Pathological images of the biopsy specimens. A, B: Diffuse infiltration of monotonous small-sized to medium-sized lymphoid cells (Hematoxylin and Eosin staining; A ×20, B ×200). C, D: Immunohistochemical staining showing positive staining for CD20 and CD5 (×100).](1349-7235-57-1751-g003){#g003}

The patient underwent ileocecal resection and ileocolic anastomosis. A gross examination of the resected specimen showed a single solid, fleshy protruding lesion, which had a cobblestone-like appearance, in the terminal ileum ([Fig. 4](#g004){ref-type="fig"}). The lesion measured 8.8×5.5 mm. There were no other polyps in the resected specimen.

![Surgically resected specimen. A: A single protruding lesion that acted as a leading point with a cobblestone-like appearance at the terminal ileum is shown. B: The sectioned surface of the lesion shows a whitish solid, fleshy lesion.](1349-7235-57-1751-g004){#g004}

The histology of the lesion in the terminal ileum revealed a monotonous population of intermediate-sized lymphoid cells with irregular nuclear and extensive submucosal infiltration into the mucosa and muscularis propria ([Fig. 5A and B](#g005){ref-type="fig"}). A flow cytometry analysis showed a monoclonal B-cell population with the following marker profile: surface immunoglobulin γ+, CD19+, CD20+, CD5+, CD3-, CD10-, CD11c-, and CD23-. An immunoperoxidase analysis performed on a glass slide showed positive nuclear staining of the tumor cells for cyclin D1 ([Fig. 5C](#g005){ref-type="fig"}). These findings were considered consistent with MCL.

![Pathological images of the surgically resected specimen. A: The lymphoid infiltrate fills the submucosa in the terminal ileal lesion \[Hematoxylin and Eosin (H&E) staining, ×4\]. B: The cells are small to medium in size with irregular nuclei, coarse chromatin, indistinct nucleoli, and pale, scant cytoplasm. Transformed lymphocytes are absent (H&E staining, ×200). C: Cyclin D1 is positive in most nuclei (×400).](1349-7235-57-1751-g005){#g005}

Thereafter, the patient underwent staging investigations. Positron emission tomography (PET) revealed no tracer uptake. A bone marrow biopsy and chromosomal study were also performed; however, no abnormal results were observed. In addition, double-balloon enteroscopy was performed to examine the small intestine, and no other lesions were noted. Based on these findings, we diagnosed the patient with primary small intestinal MCL with a single protruding lesion. The Mantle Cell Lymphoma International Prognostic Index (MIPI) score was 3.0, and the disease was classified as stage I according to the Ann Arbor staging system.

Owing to the patient\'s refusal, old age, and low MIPI score, adjuvant chemotherapy was deferred, but we carefully followed up with the patient. Postoperatively, the patient never developed symptoms. Even at three years postoperatively, upper, lower, and double-balloon endoscopic examinations have demonstrated complete remission and the absence of polypoid lesions in the gastrointestinal tract. Follow-up PET showed no abnormal hypermetabolic lesions, and there was no evidence of recurrence on abdominal CT or endoscopic examination at the latest follow-up. The patient continues to be monitored for the development of symptoms, or changes in laboratory tests or imaging studies.

Discussion
==========

MCL is a subtype of NHL, comprising about 7% of adult cases of NHL ([@B6]). Patients typically present at a median age of 60 years with lymphadenopathy and advance-stage disease (III or IV) ([@B7]). MCL is a well-defined entity characterized by the overexpression of cyclin D1 ([@B6]). Despite aggressive treatment, MCL has a poor prognosis, with a median overall survival of two to five years, because of its accelerated proliferation, non-specific clinical presentation, and early relapse ([@B7]).

MCL most commonly involves the gastrointestinal tract in the form of MLP. MLP accounts for 9% of primary gastrointestinal lymphomas ([@B3]), and approximately 10% of patients with MCL present with MLP. Multiple polyps typically involve long segments of the gastrointestinal tract. The ileocecal region is most frequently involved, whereas the esophagus and anus are rarely affected ([@B8],[@B9]). Most patients with MLP will have MCL, but this presentation may also occur in follicular lymphoma and marginal zone lymphoma ([@B8],[@B9]). There are also case reports of MLP in patients with adult T-cell leukemia/lymphoma ([@B10]) and angioimmunoblastic T-cell lymphoma ([@B11]).

The endoscopic appearances of primary gastrointestinal MCL are variable. In a report by Iwamuro et al. ([@B4]), intestinal involvement due to the MCL was identified in the gastrointestinal tract in 22 (63%) of 35 cases. In that study, the endoscopic appearance of the intestinal lesion of MCL varied: protruding type (n=4, 18%), MLP type (n=17, 77%), and superficial type (n=1, 5%). Esmadi et al. ([@B12]) also reported that the most common endoscopic feature of primary intestinal MCL is MLP, and less commonly, it presents as protruding lesions in the intestine. In addition, Chung et al. ([@B13]) reported that all six of their patients with intestinal MCL showed multiple polyposis and no protruding-type lesions.

Instead of a common presentation of MLP, our patient\'s tumor consisted of a single protruding lesion, and his symptoms of intussusception were mild and never included B symptoms, such as a fever, night sweats, or weight loss. Furthermore, while MLP behaves in an aggressive manner, MCL presenting as a single protruding lesion in the small intestine has been more indolent. At more than three years since his initial diagnosis, our patient\'s disease remains stable. However, MCL as MLP is incurable and has a mean survival rate of three years, even with chemotherapy ([@B14]).

Intussusception is rare in adults and is usually associated with a pathological mass that acts as a lead point. In the small intestine, benign neoplasms are the most common lead points, with lipomas and hamartomatous polyps occurring in most patients. In contrast, adenocarcinomas are responsible for more than 50% of intussusceptions of the colon. In addition, because the most common lymphoma that causes intussusception is diffuse large B-cell lymphoma, MCL with a single protruding lesion in the small intestine is much rarer.

Some patients with ileus as a symptom caused by intussusception attributable to MLP in the clinical course of MCL have been reported ([@B13],[@B15],[@B16]), but ileus being the real first symptom of intussusception attributable to primary small intestinal MCL has been rarely reported. Furthermore, to our knowledge, this is the first reported case of MCL with a single protruding lesion in the small intestine causing intussusception. Progress in the current patient suggested that complete remission may be achieved in MCL with a single protruding lesion in the small intestine through surgery without chemotherapy. This has enabled the patient to maintain a quality of life that may not have been possible with the side effects of chemotherapy.

A single protruding lesion is the atypical pattern of small intestinal involvement, and with this condition, a large mass causing intussusception, particularly involving the ileocecal region, is a rare but real complication. This case of primary small intestinal MCL with an unusual presentation adds to the spectra of clinical manifestations of small intestinal MCL. Primary small intestinal MCL should be included in the differential diagnosis of a single protruding lesion in the small intestine. Awareness of such occurrences is necessary and might help refine diagnostic and therapeutic methods for primary small intestinal MCL. Physicians should consider this possibility in any patient with a palpable tender mass in the right lower quadrant.

Therapy for MCL is based on the individual patient\'s risk. A simple wait-and-watch approach at the beginning is considered appropriate therapy for elderly patients or patients with a low MIPI. Chemotherapy can be started once patients develop symptoms. Initial aggressive chemotherapy with or without bone marrow transplant is recommended in young symptomatic patients. The median duration of remission is 1.5 to 3 years ([@B17]). In the current patient, the wait-and-watch approach was followed postoperatively, which was a safe option that allowed for the preservation of a good quality of life and avoidance of side effects from the early initiation of cytotoxic and biological therapies.
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